Technology
Targeted Intracellular Photodynamic Therapy (TIPT): Semorex is developing a powerful platform technology which represents a breakthrough that should allow the promise of photodynamic therapy to be realized for the treatment of most cancers. This technology was developed by Dr. Michael Firer at Ariel University in Israel, who is one of the principal investigators in our development efforts.
Our proprietary TIPT technology is a significantly more effective means of delivering photodynamic therapy - a proven treatment approved in the US, Canada and Europe for bladder, esophagus, lung, stomach and cervical cancers. In photodynamic therapy, a photosensitizer, taken-up by cancer cells, is activated by radiation from an external light to generate reactive oxygen species that induce cancer cell death. Major issues that have limited the wider application of photodynamic therapy as a treatment for cancer include: 1) the lack of photosensitizer cancer cell specificity, and 2) the need for an invasive procedure to deliver the external light as well as limited light penetration into tissue.
Semorex’s TIPT technology overcomes both of these limitations. First, the need for external light is eliminated by replacing it with intracellular chemiluminescence. Second, the specificity of the treatment is significantly improved by the targeted delivery of the active components to cancer cells via conjugation with our targeting compounds. The result of these combined improvements is a breakthrough platform technology potentially broadly applicable to most types of cancer including hematological malignancies as well as other major cancers such as lung, breast, colon, ovarian, liver and prostate.
Molecularly Imprinted Polymers: Our proprietary technology, which combines advances in polymer chemistry and immunochemistry, enables us to make molecularly imprinted polymers (MIPs) designed for selective recognition of target compounds. We use these MIPs for the removal of unwanted compounds from the patients’ body.
|
|
